Investigating the effect of magnesium sulfate nebulization in children with cystic fibrosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231031059919N1

Enrollment

Registered

2024-01-08

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis. Cystic fibrosis with pulmonary manifestations

Interventions

Intervention 1: Intervention group: Cystic fibrosis patients who meet the inclusion criteria. During the sampling, first stage data will be collected from the patients. which includes performing a bas

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: Suffering from cystic fibrosis Over 6 years old Ability to perform spirometry FEV1 above 60%

Exclusion criteria

Exclusion criteria: Nnon-cooperation in the continuation of the intervention Drug intolerance Nebulizer intolerance The patient's entry into the exacerbation phase Inability to perform spirometry

Design outcomes

Primary

Measure	Time frame
FEV1 index of spirometry in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FVC index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FEV1/FVC index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FEF25-75 index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;The score obtained from the Schwach-Man instrument in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.	—

Measure

Time frame

FEV1 index of spirometry in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FVC index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FEV1/FVC index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FEF25-75 index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;The score obtained from the Schwach-Man instrument in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.

—

Secondary

Measure	Time frame
. Timepoint: . Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Zibaei

Mashhad University of Medical Sciences

mitrazibaei@gmail.com+98 51 3841 1538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026